May 19, 2016
 |
| A-B: Immunocytochemistry in SNCA triplication (A6) NSCs with antibodies against NSC markers SOX1, NESTIN, and PAX6. C-D: Immunocytochemistry for dopaminergic (TH and LMX1A), and midbrain (FOXA2) markers. Scale bar as marked. |
Parkinson's
disease (PD), a chronic, progressive and devastating neurodegenerative motor
disease affecting as many as one million Americans, is complex. Its causes
likely include a combination of genetic, environmental and other lifestyle
factors that influence gene expression. While progress has been made, a
fundamental understanding of how the disease develops on the molecular level
is still lacking, due in large part because there is no good way to model the
disease. Research from the Buck Institute is poised to change that. Buck
Institute faculty Xianmin Zeng, PhD, has derived 10 induced pluripotent stem
cells (iPSC) lines from PD patients and is in the process of depositing those
lines along with a wealth of related genomic information about them into an
NIH-approved facility for use by the larger research community. Details about
the iPSC lines will publish in PLOS One on Wednesday, May 18.
"We think this is the largest collection of patient-derived lines generated at an academic institute," said Zeng, who is also developing a stem cell replacement therapy for PD. "We believe the lines and the datasets we have generated from them will be a valuable resource for use in modeling PD and for the development of new therapeutics." Given the aging of the population and the fact that current therapies only address symptoms, the need for a relevant disease model for PD is urgent. Affected neurons cannot be obtained from PD patients (except for post-mortem tissue which has limited value) and Zeng says animal studies, while valuable often provide an inadequate representation of what occurs in human patients.
The iPSCs were made from skin cells donated by PD patients carrying the most common mutations linked to the disease: SNCA, LRRK2, PARK2 and GBA. Using an integration-free method which minimized genomic
alteration,
the cells were reprogrammed to behave like embryonic stem
cells and then were coaxed into becoming dopaminergic neurons, the
nerve cells affected in PD. Whole genome expression analysis was done at each
stage of differentiation.
"This
work combined with dozens of other control, isogenic and reporter iPSC lines
developed by Dr. Zeng will enable researchers to model PD in a dish," said
Brian Kennedy, PhD, Buck Institute President and CEO. "Her work, which we
are extremely proud of, will help researchers dissect how genes interact with
each other to cause PD, and assist scientists to better understand what
experimental drugs are doing at the molecular level to decide
what drugs to use based on mutations."
In
addition to aiding drug development Zeng hopes the cell lines will also be used
to develop biomarkers of PD that would enable the identification of patients at
risk prior to the onset of the disease.
Explore further: Scientists accelerate aging in stem cells to study age-related diseases like Parkinson's |
| A: Schematic representation of the reprogramming process. B: Immunocytochemistry for pluripotency factors OCT4, NANOG, SOX2, and TRA1-60. C: Alkaline phosphatase reactivity. Inserts: Images taken at higher magnification. D: qPCR analysis of total and endogenous expression of pluripotency genes OCT4, SOX2, and NANOG. ACTB served as an endogenous reference, and data were normalized against ESC sample. E: Immunocytochemistry for markers of the three germ layers in embryoid bodies. Scale bar as marked. F: qPCR analysis of the expression of SeV-specific transcripts. ACTB served as an endogenous reference, and data were normalized against SeV sample (cells collected a week after transduction with SeV). Fold change is shown on logarithmic scale G: Karyotype analysis in SNCAtriplication line A6. H: STR profiles of parent fibroblast and iPSC A6 line.. |
More information: Olga Momcilovic et al. Derivation, Characterization, and Neural Differentiation of Integration-Free Induced Pluripotent Stem Cell Lines from Parkinson's Disease Patients Carrying SNCA, LRRK2, PARK2, and GBA Mutations, PLOS ONE (2016). DOI: 10.1371/journal.pone.0154890
http://medicalxpress.com/news/2016-05-link-parkinson-disease-therapeutics.html
No comments:
Post a Comment